Allyx Therapeutics is a clinical-stage biotechnology company developing regenerative medicine therapies aimed at restoring neuronal function in patients with neurodegenerative diseases. Their approach focuses on enhancing cognitive health by targeting the underlying mechanisms of neurodegeneration.

Alphina Therapeutics develops antibody-drug conjugates (ADCs) that utilize novel NAMPT inhibitor payloads to target and eliminate both dividing and non-dividing tumor cells. The company pairs these next-generation ADC candidates with a proprietary diagnostic test to precisely identify patients most likely to respond to NAMPT inhibitor therapy. This precision approach aims to deliver superior, effective cancer treatments for a broader patient population than existing targeted therapies.

Alva Health develops patented wearable devices that continuously monitor for stroke indicators and connect users with emergency responders in real-time. This technology addresses the critical issue of delayed medical care, as 90% of stroke victims do not receive timely treatment, leading to increased disability and healthcare costs.

Artizan Biosciences specializes in drug discovery and development targeting diseases linked to the human intestinal microbiota through advanced microbiome analysis and therapeutic interventions. The company aims to improve patient outcomes by developing precise treatments that restore microbial balance and enhance gut health.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

Ascent Bio provides an AI scientist platform designed to augment drug development workflows for researchers. This agentic system accelerates scientific discovery by offering a unified, capable tool for complex research tasks. The platform aims to significantly increase the productivity of scientists engaged in pharmaceutical design and research.

AtlasXomics provides a spatial epigenome mapping solution at the single-cell level using the FlowGel220 kit, enabling precise analysis of gene regulation in oncology, neurology, and aging research. This technology addresses the need for high-resolution spatial context in epigenomic studies, facilitating a deeper understanding of cellular behavior and disease mechanisms.

The startup offers a novel observability platform that utilizes distributed tracing and real-time metrics to enhance system performance monitoring. This approach enables organizations to identify and resolve performance bottlenecks quickly, improving operational efficiency and reducing downtime.

The startup operates an online retail marketplace that connects customers with surplus and deadstock building materials and DIY products from retailers. By offering these goods at significantly reduced prices, the platform addresses the issue of waste in the construction industry while providing affordable options for consumers.